Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.
Level 5 - mechanism / opinion, no new human data
Scoping review of literature without a formal systematic review protocol or meta-analytic pooling of trials
PubMed 41704988 · doi:10.7759/cureus.101693
What was done
The authors conducted a scoping review searching PubMed and Embase to evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on weight loss, central adiposity, vasomotor symptoms, and cardiovascular markers specifically in menopausal and postmenopausal women. Articles were selected based on title and abstract relevance, study design, and metabolic variables.
What was found
The abstract reports no quantitative values, effect sizes, or counts of included studies. Narratively, the reviewed literature reported that GLP-1RAs were associated with increased weight loss and reduced central adiposity in menopausal and postmenopausal women, with limited studies also noting improvements in vasomotor symptoms and cardiovascular markers.
Why it matters
This review collates early evidence on whether GLP-1 receptor agonists address the distinct metabolic changes and vasomotor symptoms experienced by women during and after menopause.
Limits
No quantitative data, effect estimates, or study counts are reported in the abstract. As a scoping review of limited available literature, conclusions are preliminary, and effects on outcomes like bone density and cardiovascular markers remain insufficiently characterized.
Cited by
- context Studies show that women taking GLP-1 receptor agonists like tirzepatide achieve greater weight loss when also receiving hormone replacement therapy (HRT).